Guo Shuang, Zhao Junlai, Zhu Rongrong, Fan Zhi, Liu Shibiao, Wu Weiwei
Department of Vascular Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Front Pharmacol. 2025 Jul 16;16:1638240. doi: 10.3389/fphar.2025.1638240. eCollection 2025.
Emerging evidence positions the gut microbiota as a pivotal regulator of host metabolism and immunity, particularly in atherosclerosis pathogenesis, with epigenetic mechanisms serving as fundamental mediators of gene expression control. This review systematically summarizes gut microbiome-driven epigenetic pathways, encompassing DNA methylation, histone modifications, non-coding RNA networks and their interplay with atherosclerosis-related pathological processes. We synthesize current evidence on microbiota-epigenome crosstalk, highlighting its potential mechanistic contributions to atherosclerotic plaque development.
新出现的证据表明,肠道微生物群是宿主代谢和免疫的关键调节因子,尤其是在动脉粥样硬化发病机制中,表观遗传机制是基因表达控制的基本介质。本综述系统地总结了肠道微生物群驱动的表观遗传途径,包括DNA甲基化、组蛋白修饰、非编码RNA网络及其与动脉粥样硬化相关病理过程的相互作用。我们综合了目前关于微生物群-表观基因组相互作用的证据,强调了其对动脉粥样硬化斑块发展的潜在机制贡献。